TrialCancer science2016

Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer-WJOG 6210G.

Kohei Shitara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.